Description: Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company utilizes its microRNA product platform to develop anti-miRs, a chemically modified single-stranded oligonucleotides. Its microRNA development candidates target miR-122 in hepatitis C virus infection; miR-21 and miR-221 in hepatocellular carcinoma; miR-21 in kidney fibrosis; miR-33 in atherosclerosis; and miR-10b in glioblastoma. The company has strategic alliances with AstraZeneca AB, GlaxoSmithKline plc, Sanofi, and Alnylam and Isis, as well as a strategic collaboration with Biogen Idec MA Inc. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Home Page: www.regulusrx.com
RGLS Technical Analysis
4224 Campus Point Court
San Diego,
CA
92121
United States
Phone:
858 202 6300
Officers
| Name | Title |
|---|---|
| Mr. Joseph P. Hagan M.B.A. | Pres, CEO & Director |
| Ms. Crispina Calsada CPA | Chief Financial Officer |
| Mr. Christopher Ray Aker J.D. | Sr. VP, Gen. Counsel & Corp. Sec. |
| Mr. Daniel J. Penksa | Sr. Director of Fin. & Controller |
| Mr. Firuz Shakoori | Head of CMC |
| Dr. Claire Susan Padgett M.S., M.T., Ph.D. | Sr. VP of Clinical Operations |
| Dr. Rekha Garg M.D., M.S. | Sr. VP of Clinical Devel. & Regulatory |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5859 |
| Price-to-Sales TTM: | 7.4299 |
| IPO Date: | 2012-10-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 27 |